Destiny Pharma Limited is an innovative pharmaceutical company founded in 1997 to identify and generate high value pharmaceutical intellectual property.

The company is focused on the scientific discovery and early-stage clinical development of highly innovative antimicrobials, through to the point where products can be profitably on-licensed to major pharmaceutical companies for clinical development and exploitation.

Destiny Pharma is a well-managed company with a track record of innovation. The company selects projects on a strictly commercial basis and project manages these using world-class teams, assembled on a project-by-project basis, to undertake research and development.

Destiny Pharma's lead drug, XF-73, is in clinical development and the company will license/partner for onward development and commercialisation of the technology.